Literature DB >> 8314809

Improved cortical histology after cementation with a new MMA-DMA-IBMA bone cement: an animal study.

L Nimb1, J Stürup, J S Jensen.   

Abstract

The histological response of bone to inert bone wax, conventional polymethylmethacrylate (PMMA), and a new formulation of bone cement, methylmethacrylate/n-decylmethacrylate/isobornylmethacrylate (MMA/DMA/IBMA) was investigated in canine tibial diaphysis. The new formulation of cement is characterized by a reduced exothermic temperature at curing and reduced leakage of chemicals to the adjacent bone. In comparison with bone wax, the MMA/DMA/IBMA bone cement did not differ significantly with respect to periosteal apposition and bone remodeling, although a tendency to inhibit the biological response was encountered. The MMA/DMA/IBMA was clearly superior to PMMA bone cement in respect to both bone necrosis and repair, as well as bone remodeling.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314809     DOI: 10.1002/jbm.820270503

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  3 in total

1.  No biological advantage with a low temperature curing versus a conventional bone cement: an experimental, mechanical and histomorphometrical study in the rabbit tibia.

Authors:  P Morberg; C B Johansson; H Malchau
Journal:  J Mater Sci Mater Med       Date:  1999-06       Impact factor: 3.896

2.  Risk factors of adjacent vertebral collapse after percutaneous vertebroplasty for osteoporotic vertebral fracture in postmenopausal women.

Authors:  Kenji Takahara; Mikio Kamimura; Hideki Moriya; Ryohei Ashizawa; Tsuyoshi Koike; Yohei Hidai; Shota Ikegami; Yukio Nakamura; Hiroyuki Kato
Journal:  BMC Musculoskelet Disord       Date:  2016-01-12       Impact factor: 2.362

3.  10-year results of a new low-monomer cement: follow-up of a randomized RSA study.

Authors:  Per Söderlund; Jon Dahl; Stephan Röhrl; Bo Nivbrant; Kjell G Nilsson
Journal:  Acta Orthop       Date:  2012-11-01       Impact factor: 3.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.